← Back to Search

Placebo

Subconjunctival Injection of Local Anesthetic in Anterior Blepharoptosis Repair

N/A
Waitlist Available
Led By Matthew Lee-Wing, MD
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 years

Summary

This trial is testing whether injecting local anesthetic through the back of the eyelid reduces pain during a common surgical procedure to fix droopy eyelids.

Eligible Conditions
  • Drooping Eyelid
  • Blepharoptosis
  • Droopy Eyelid

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
0-10 Numerical Pain Scale
Secondary study objectives
Post-Operative margin-reflex distance 1
Presence of post-operative lagophthalmos/fluorescein staining

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Subcut. + Subconj. InjectionExperimental Treatment2 Interventions
Patients will undergo standard blepharoptosis repair using an anterior approach, with an added injection of local anesthetic (Xylocaine) beneath the conjunctiva of the lid being operated on. They will still receive the standard subcutaneous local anesthetic given during blepharoptosis repair.
Group II: Subcut. + Sham Subconj. InjectionPlacebo Group2 Interventions
Patients will undergo standard blepharoptosis repair using an anterior approach, however they will not receive the additional subconjunctival Xylocaine injection. Instead, they will receive a sham injection of Normal Saline to prevent them from knowing which eye received the additional anesthetic.

Find a Location

Who is running the clinical trial?

University of ManitobaLead Sponsor
621 Previous Clinical Trials
206,463 Total Patients Enrolled
Matthew Lee-Wing, MDPrincipal InvestigatorUniversity of Manitoba
~12 spots leftby Dec 2025